Fulcrum Therapeutics Inc. (FULC) Misses Q2 EPS by 17c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($0.83), $0.17 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $1.88 million versus the consensus estimate of $2.96 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• United Community Banks sells equipment finance unit for $1.9 billion
• Medtronic completes $550 million Scientia Vascular acquisition